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ABSTRACT
Objectives: The objective of this report is to provide guidance and rec-
ommendations on how drug costs should be measured for cost-
effectiveness analyses conducted from the perspective of a managed care
organization (MCO).
Methods: The International Society for Pharmacoeconomics and Out-
comes Research (ISPOR) Task Force on Good Research Practices—Use of
Drug Costs for Cost Effectiveness Analysis (DCTF) was appointed by the
ISPOR Board of Directors. Members were experienced developers or users
of CEA models. The DCTF met to develop core assumptions and an
outline before preparing a draft report. They solicited comments on drafts
from external reviewers and from the ISPOR membership at ISPOR meet-
ings and via the ISPOR Web site.
Results: The cost of a drug to an MCO equals the amount it pays to
the dispenser for the drug’s ingredient cost and dispensing fee minus the
patient copay and any rebates paid by the drug’s manufacturer. The
amount that an MCO reimburses for each of these components can differ
substantially across a number of factors that include type of drug (single
vs. multisource), dispensing site (retail vs. mail order), and site of admin-
istration (self-administered vs. physician’s ofﬁce). Accurately estimating
the value of cost components is difﬁcult because they are determined by
proprietary and conﬁdential contracts.
Conclusion: Estimates of drug cost from the MCO perspective should
include amounts paid for medication ingredients and dispensing fees, and
net out copays, rebates, and other drug price reductions. Because of the
evolving nature of drug pricing, ISPOR should publish a Web site where
current DCTF costing recommendations are updated as new information
becomes available.
Keywords: costs, cost-effectiveness analysis, drug costs, economic analysis,
managed care.
Background to theTask Force
The International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) Task Force on Good Research Practices—Use
of Drug Costs for Cost Effectiveness Analysis (DCTF) was rec-
ommended by the ISPOR Health Science Policy Council on
December 13, 2004 and was approved by the ISPOR Board of
Directors on May 15, 2005. Because how drug costs should be
measured for CEAs depends on the perspectives, ﬁve Task Force
subgroups were created to develop drug costs standards from the
societal, managed care, US government, industry, and interna-
tional perspective. This report is part III: a managed care per-
spective (one of six reports from this ISPOR Task Force on Good
Research Practices—Use of Drug Costs for Cost Effectiveness
Analysis [DCTF]). The other reports (part I: issues and recom-
mendations; part II: a societal perspective; part IV: US govern-
ment perspective; part V: industry perspective; and part VI:
international perspective) are also published in this issue of Value
in Health. This DCTF subgroup met to develop core assumptions
and an outline before preparing a draft report. The Task Force
subgroups held open forums and/or group leader breakfast meet-
ings at the ISPOR Annual International Meetings and European
Congresses. The draft report was circulated to 174 Task Force
primary reviewers (who were self-identiﬁed from a broad range
of perspectives). After this review, a new draft was prepared and
made accessible for broader review by all ISPOR members. Com-
ments for these reports by Task Force primary reviewers and
ISPOR membership are published at the ISPOR Web site. All
opinions reﬂect those of the authors and not necessarily their
afﬁliations.
Introduction
The objective of the ISPOR Task Force on Good Research
Practices—Use of Drug Costs for Cost Effectiveness Analysis
(DCTF) is to develop standards for using drug costs in phar-
macoeconomic studies. The managed care subgroup focused on
estimating drug costs to a managed care organization (MCO)
within the US health-care context. An MCO is an organization
that is paid to manage the accessibility, ﬁnancing, provision,
quality, and cost of health care delivered to a speciﬁc popula-
tion of individuals [1–3]. Because of the complex nature of the
pharmaceutical purchase process within the United States, the
actual cost faced by an MCO is generally lower than that sug-
gested by published prices. It is also usually different than the
cost faced by patients, providers, and government agencies
[4,5].
The following sections will explain the process by which the
report was developed, identify and explain the components and
considerations that determine the cost of a drug to anMCO, and,
where possible, identify potential sources for estimates of those
components. It will also provide recommendations on standards
that should be employed when doing pharmacoeconomic assess-
ments from an MCO perspective.
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Drug Cost Components
Generally speaking, the cost of a drug to an MCO equals the
amount it pays to the dispenser (usually a pharmacy) to cover the
drug’s “ingredient cost” and dispensing fee minus the patient
copay and any rebates paid to the MCO by the manufacturer of
the drug (the “ingredient cost” refers to the cost of the medicine,
whereas the dispensing fee refers to the cost of pharmacists’
services rendered in dispensing the prescription). The value of
each of these components can differ substantially across a
number of factors [4,5]. These include, for example, type of drug
(single vs. multisource), dispensing site (retail vs. mail order), and
site of administration (self-administered vs. physician’s ofﬁce).
Adding to the complexity is a lack of transparency in pricing. The
value of most components is determined by a proprietary and
conﬁdential contract. Finally, the nature of drug pricing and
reimbursement is constantly evolving. Hence, recommendations
for MCO drug costing should be applied thoughtfully, with
adjustments made for new developments that occur before the
time that a pharmacoeconomic analysis is conducted.
Single-Source Products
For products that are branded and still under patent protection
(single-source products), the amount that an MCO pays a phar-
macy for ingredient cost has traditionally been based on the
average wholesale price (AWP) minus some percentage [4,5]. The
percent discount is negotiated between the MCO, or its phar-
macy beneﬁt manager (PBM), and the retail and mail-order phar-
macies in its network. The Pharmacy Beneﬁt Management
Institute (PBMI), an organization that annually surveys health
beneﬁt managers in employer-provided health plans, indicates
that mean discounts were 16% for retail pharmacies and 23%
for mail-order pharmacies during 2008 [6]. The dispensing fee is
also negotiated between the MCO (or its PBM) and pharmacies.
PBMI indicates that for 2008, mean dispensing fees were $1.73
for retail pharmacies and $2.17 for those mail-order pharmacies
that charged dispensing fees; however, only about 20% of mail-
order pharmacies charged dispensing fees [6]. Note that retail
pharmacy fees are for a 1-month supply, whereas mail-order
dispensing fees cover a 3-month supply. Over the past several
years, ingredient cost discounts have been increasing and reim-
bursements for dispensing fees have been decreasing [6].
The MCO’s drug cost is reduced by the portion of the ingre-
dient cost and dispensing fee that is paid by the patient, i.e., the
patient copay, as well as any reimbursement made to the MCO in
the form of a manufacturer rebate. The size of the patient copay
depends on the formulary tier to which the drug is assigned and on
whether the drug is dispensed by a retail or mail-order pharmacy
[6]. Most single-source drugs are given second or third-tier for-
mulary status. Exceptions typically include lifestyle drugs, spe-
cialty pharmaceuticals, and products administered by a physician
(which generally receive special formulary status). PBMI indicates
that second and third-tier copays for retail purchases averaged
$24 and $42, respectively, in 2008 [6]. The size of copays, as well
as the difference between those for second and third-tier drugs, has
been increasing over time [6,7]. In addition, payers have increased
their use of coinsurance in recent years as an alternative to ﬁxed
dollar copays [6]. The size of the copay also depends on whether
the drug is dispensed at a retail or mail-order pharmacy. Histori-
cally, MCOs have offered patients the option of getting a 3-month
supply at mail order for the equivalent of two retail monthly
copays. Nevertheless, in recent years, there has been a trend to use
somewhat higher mail-order copays [6]. Mail copays for 2008 for
second and third-tier drugs were $49 and $84, respectively [6].
The Federal Trade Commission has estimated that the
average manufacturer rebate paid to an MCO for a single-source
drug in 2003 was about 7.5% of catalog price, also known as
wholesale acquisition cost (WAC) [4,8]. Nevertheless, the rebate
usually varies with the formulary status granted to the drug as
well as the degree of in-class competition [5]. Based on the
limited information that we were able to gather, an analyst can
reasonably assume a base-case rebate of 15%, with a range from
5% to 25% for a second-tier drug with in-class competitors,
none of which is available generically [9]. If that product were
placed on the third tier, a signiﬁcantly smaller rebate would
typically be granted by the manufacturer. If the drug had no
in-class competitors, then a much smaller rebate, or no rebate,
would be reasonable for both second and third-tier drugs. Drugs
that have a generic in-class competitor that is clinically similar to
the branded medicine may earn much higher rebates. Note that
the rebate percentage applies to the manufacturer’s catalog price
for the drug (i.e., WAC).
Using industry sources, one author estimated that approxi-
mately 20% of manufacturer rebates are retained by PBMs, the
organizations that administer the drug beneﬁt for the MCOs
[10]. In most cases, PBMs are independent external organiza-
tions, but in some cases, they are internal subsidiaries of the
MCO. Either way, the services they provide are a necessary part
of the drug acquisition and delivery process. As such, the portion
of the rebate that they retain should be considered part of the
MCOs’ drug cost. For this reason, when subtracting the manu-
facturer rebate to arrive at the ﬁnal net cost to the MCO, the
analyst should exclude that portion of the rebate retained by the
PBM. For example, if the total rebate is $100 and the PBM keeps
20% of it, then only $80 should be subtracted to arrive at the
ﬁnal cost to the MCO.
Multisource Products
The same factors govern the cost of multisource drugs—those
that are available from multiple manufacturers or repackagers.
These are commonly referred to as “generics.” Nevertheless,
there are important differences in the estimation of the drug cost
components. MCOs usually do not earn rebates on multisource
drugs [5]. Because the decision of which multisource products to
dispense is made at the pharmacy level, price considerations
usually accrue to the pharmacy rather than to the MCO [4].
Most generics are listed on the ﬁrst formulary tier and, thus, are
subject to the lowest copay [5]. Average ﬁrst-tier copays in 2008
averaged about $10 for retail pharmacies and about $19 for
mail-order purchases [6].
Ingredient costs for multisource products are more difﬁcult to
determine because most are distributed by a large number of
companies at a wide range of prices. Furthermore, list prices are
typically much higher than what pharmacies actually pay [11].
MCOs typically deal with this situation by establishing
maximum allowable cost (MAC) lists for multisource products.
These lists establish a maximum amount that the MCO will
reimburse a pharmacy for a multisource product. MCOs and
PBMs consider their MAC lists to be proprietary and conﬁden-
tial. As a further complication, MCOs may use MAC pricing for
retail pharmacies and discounted AWP for mail-order pharma-
cies [6]. Dispensing fees for multisource products are typically
the same as those for branded products, although MCOs will
occasionally provide higher dispensing fees to encourage phar-
macists to dispense them.
Most contracts specify that the MCO will pay the pharmacy
the lesser of the contract price (i.e., MAC plus dispensing fee) or
the pharmacy’s usual and customary price to cash patients [5].
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Consequently, pharmacies’ prices to cash customers represent an
alternative source of cost information. For many pharmacies,
these prices are available online. Examples include costco.com,
drugstore.com, and cvs.com. The lists of “$4 generics” posted by
Wal-Mart, Kroger, and Target stores represent yet another source
of information. Whether pharmacies are reimbursed at the usual
and customary price, or at the contract price, the cost to the
MCO is reduced by the amount of the patient copay.
It is worth noting that the costs of multisource products are
small relative to the costs of single-source products or other
health-care costs. As a result, less precise estimates of generic
prices do not typically have a large impact on pharmacoeco-
nomic analyses.
Physician-Administered Drugs
Some drugs are not delivered to patients through pharmacies but
are administered via infusion or injection in physician ofﬁces or
hospital outpatient clinics. MCOs have tended to follow Medi-
care Part B in their compensation for physician-administered
drugs. Until recently, Medicare reimbursement for such medi-
cines was 85% of AWP [12,13]. Nevertheless, that included the
20% patient coinsurance. Medicare thus paid 80% of 85%,
equal to 68% of AWP. Thus, 68% of AWP was a reasonable basis
from which to estimate the cost of these drugs to MCOs.
The federal government recently changed its reimbursement
from 85% of AWP to average sales price (ASP) plus 6% [5,14].
ASP is a relatively new pricing concept developed by the Centers
for Medicare and Medicaid Services (CMS) for the reimburse-
ment of drugs covered under Medicare Part B. Although the ASP
amounts are not made public, the amounts representing 106% of
ASP are available publicly via the CMS Web site (http://
www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/). With coinsur-
ance of 20%, the new net Medicare reimbursement for a drug
would be 80% of 106% of ASP, or 84.8% of ASP. Note,
however, that not all managed care payers have adopted this new
reimbursement level [15–17]. They have, however, become more
aggressive in demanding and extracting rebates. Therefore, when
estimating the cost of physician-administered drugs, the analyst
should consider using the smaller of 68% of AWP or 84.8% of
ASP. Nevertheless, given the pluralism of managed care payment
levels, we also recommend performing sensitivity analysis using
the higher of the two options, thus enabling readers to choose the
estimate that is closest to their own experience.
Conclusion
Drug prices paid by MCOs are based on ingredient cost and
dispensing fee reimbursements, less manufacturer rebates and
patient copays. Each of these components can vary based on such
factors as dispensing site, site of administration, type of product,
and formulary placement. Further, drug pricing is dynamic. Con-
sideration of the factors discussed in this report should lead the
analyst to a price that is considerably more accurate than the
published list prices, such as AWP, typically used in pharmaco-
economic analyses.
Task Force Recommendations
Pharmacoeconomic analyses, as well as budget impact analyses,
done from an MCO perspective should reﬂect as carefully as
possible the prices actually paid by the MCOs net of all rebates,
copays, or other adjustments. This is not easy because these
prices are currently in a state of ﬂux; AWP amounts may not be
available in the future. One alternative benchmark, ASP + 6%, is
currently available through CMS, but only for drugs covered
under Medicare Part B. Yet another benchmark, the average
manufacturer’s price (AMP), may eventually be published by
CMS as mandated by law, but this is currently being challenged
in court and the outcome is uncertain [18,19].
• Pharmacoeconomic researchers should keep current as to
which data source (WAC, AWP, ASP, AMP, etc.) provides
the most comprehensive and transparent basis for establish-
ing drug prices used by MCOs.
• When doing a pharmacoeconomic assessment from the
MCO perspective, to the extent possible, the drug cost
should include amounts paid for medication ingredients and
dispensing fees, and net out rebates, patient copays, volume
discounts, or any other drug price reductions that are rel-
evant to the MCO environment.
• In estimating drug costs, analysts should make adjustments
for the proportion of medication dispensed through retail
and mail-order pharmacies, and any resulting variation in
dispensing fees or reimbursement for ingredient costs.
• In estimating drug costs, analysts should make adjustments
for whether the medication is administered by a physician
or has other special characteristics that make its coverage
different from the typical medication dispensed in a retail
pharmacy or by mail order.
• Recognizing that different MCOs may face somewhat dif-
ferent rebates and pricing structures, pharmacoeconomic
researchers should include, in sensitivity analyses, pricing
variation that reﬂects reasonable ranges in fully discounted
MCO prices.
• For drugs that are off patent or likely to be off patent in the
near future, particularly when looking at treatments for
chronic diseases, it is appropriate to consider multisource
drug prices in either the base-case or sensitivity analyses of
pharmacoeconomic models.
• ISPOR should publish a Web site where current DCTF
recommendations for managed care drug costing are
updated as important new information becomes available.
Source of ﬁnancial support: The article was prepared without a contract or
funding from a sponsor.
References
1 Folland S, Goodman AC, Stano M. The Economics of Health and
Health Care, (5th ed.). Upper Saddle River, NJ: Pearson Prentice
Hall, 2007.
2 Nash DB. The Managed Care Manual. Boston: TLC Medical
Publishing, 1997.
3 Berger L, Bingefors K, Hedblom E, et al., eds. Health Care Cost,
Quality, and Outcomes: ISPOR Book of Terms. Princeton, NJ:
International Society for Pharmacoeconomics and Outcomes
Research, 2003.
4 Congressional Budget Ofﬁce. Prescription Drug Pricing in the
Private Sector. Washington, DC: Congressional Budget Ofﬁce,
2007.
5 AMCP Task Force on Drug Payment Methodologies. AMCP
Guide to Pharmaceutical Payment Methods. Alexandria, VA:
Academy of Managed Care Pharmacy, 2007.
6 Pharmacy Beneﬁt Management Institute. The Takeda Prescription
Drug Beneﬁt Cost & Plan Design Survey Report: 2008–2009
Edition. Scottsdale, AZ: Pharmacy Beneﬁt Management Institute,
Inc., 2008.
7 Claxton G, DiJulio B, Finder B, et al. Employer Health Beneﬁts:
2007 Annual Survey. Menlo Park, CA: Henry J. Kaiser Family
Foundation, 2007.
8 Wroblewski M, Schmidt D, Schultheiss P, et al. Pharmacy Beneﬁt
Managers: Ownership of Mail-Order Pharmacies. Washington,
DC: Federal Trade Commission, 2005.
16 Mansley et al.
9 Health Strategies Group. Best Practices, Reimbursement and
Contracting Outlook 2007. Lambertville, NJ: Health Strategies
Group, 2005.
10 Smith C. Retail prescription drug spending in the National Health
Accounts. Health Aff 2004;23:161–7.
11 Ofﬁce of the Inspector General. Medicaid Pharmacy—Actual
Acquisition Cost of Generic Prescription Drug Products A-06-01-
00053. Washington, DC: Department of Health and Human Ser-
vices, 2002.
12 Gencarelli DM. Average wholesale price for prescription drugs: is
there a more appropriate pricing mechanism? NHPF Issue Brief
2002;1–19.
13 Gencarelli DM. One pill, many prices: variation in prescription
drug prices in selected government programs. NHPF Issue Brief
2005;1–20.
14 Centers for Medicare and Medicaid Services. Overview Medicare
Part B drug average sales price. Center for Medicare and Medi-
caid Services Website, 2009. Available from: http://www.cms.
hhs.gov/mcrpartbdrugavgsalesprice/ [Accessed September 24,
2009].
15 EMD Serono Injectables Digest (4th ed.). Rockland, MA: EMD
Serono, Inc., 2008.
16 Mullen P. The arrival of average sales price. Biotechnol Healthc
2007;4:48–53.
17 Butcher L. Insurers and oncologists forge a better cancer drug
policy. Manag Care 2008;17:28–30.
18 Paul R. Bracing for a showdown. Drug Topics 2008;152:30–7.
19 Latebreakers: AWP is back from the dead. Drug Topics
2008;152:8.
Measuring Drug Costs for Managed Care CEAs 17
